Tom Howing In this job you get to meet a lot of remarkable people, none more so than the patients who volunteer to take part in what are giant experiments. They are courageous pioneers, willing to be among the first people to ever try a new therapy, knowing that it may not help them and, … Continue reading Saying thanks and farewell to a friend
Forty Seven
A word from our Chair, several in fact
In 2005, the New Oxford American Dictionary named “podcast" its word of the year. At the time a podcast was something many had heard of but not that many actually tuned in to. My how times have changed. Now there are some two million podcasts to chose from, at least according to the New York … Continue reading A word from our Chair, several in fact
Cures, clinical trials and unmet medical needs
When you have a great story to tell there’s no shame in repeating it as often as you can. After all, not everyone gets to hear first time around. Or second or third time. So that’s why we wanted to give you another opportunity to tune into some of the great presentations and discussions at … Continue reading Cures, clinical trials and unmet medical needs
CIRM-funded treatment for cancer granted FDA breakthrough therapy designation
Mark Chao, M.D., Ph.D., cofounder of Forty Seven, Inc. and current VP of oncology clinical research at Gilead Sciences An antibody therapeutic, magrolimab, being tested for myelodysplastic syndrome (MDS), a group of cancers in which the bone marrow does not produce enough healthy blood cells , was granted breakthrough therapy designation with the Food and Drug Administration … Continue reading CIRM-funded treatment for cancer granted FDA breakthrough therapy designation
Meet the people who are changing the future
Kristin MacDonald Every so often you hear a story and your first reaction is “oh, I have to share this with someone, anyone, everyone.” That’s what happened to me the other day. I was talking with Kristin MacDonald, an amazing woman, a fierce patient advocate and someone who took part in a CIRM-funded clinical trial … Continue reading Meet the people who are changing the future
Perseverance: from theory to therapy. Our story over the last year – and a half
Some of the stars of our Annual Report It’s been a long time coming. Eighteen months to be precise. Which is a peculiarly long time for an Annual Report. The world is certainly a very different place today than when we started, and yet our core mission hasn’t changed at all, except to spring into … Continue reading Perseverance: from theory to therapy. Our story over the last year – and a half
Big time validation for early support
It’s not every day that a company and a concept that you helped support from the very beginning gets snapped up for $4.9 billion. But that’s what is happening with Forty Seven Inc. and their anti-cancer therapies. Gilead, another California company by the way, has announced it is buying Forty Seven Inc. for almost $5 … Continue reading Big time validation for early support
CIRM Board Meeting Highlights Important Updates to Clinical Trials
Dr. Maria T. Millan, President and CEO of CIRM, presenting the President's Report This past Thursday the governing Board of the California Institute for Regenerative Medicine (CIRM) were presented with an update on CIRM’s clinical portfolio, which to date includes 60 clinical trials in various areas including kidney failure, cancer, and other rare diseases. The … Continue reading CIRM Board Meeting Highlights Important Updates to Clinical Trials
Facebook Live: Ask the Stem Cell Team
On December 12th we hosted our latest 'Facebook Live: Ask the Stem Cell Team' event. This time around we really did mean team. We had a host of our Science Officers answering questions from friends and supporters of CIRM. We got a lot of questions and didn't have enough time to address them all. So … Continue reading Facebook Live: Ask the Stem Cell Team
Four CIRM Funded Trials Release Results at 2019 ASH Meeting
With more than 17,000 members from nearly 100 countries, the American Society of Hematology (ASH) is an organization composed of clinicians and scientists around the world working to conquer various blood diseases. Currently, they are having their 61st Annual ASH Meeting to highlight some of the exciting work going on in the field. Four of … Continue reading Four CIRM Funded Trials Release Results at 2019 ASH Meeting
The Stem Cellar 